Meeting
2022 ASCO Genitourinary Cancers Symposium
The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
Authors
Kim N. Chi
BC Cancer and Vancouver Prostate Centre, Vancouver, BC, Canada
Kim N. Chi , Axel S. Merseburger , Mustafa Ozguroglu , Simon Chowdhury , Anders Bjartell , Byung Chung , Andrea Juliana Pereira de Santana Gomes , Robert Given , Álvaro Juárez , Hirotsugu Uemura , Dingwei Ye , Lawrence Ivan Karsh , Benjamin Adam Gartrell , Sabine D. Brookman-May , Suneel Mundle , Sharon Anne McCarthy , Florence Lefresne , Oliver Brendan Rooney , Amitabha Bhaumik , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02489318
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 89)
DOI
10.1200/JCO.2022.40.6_suppl.089
Abstract #
89
Poster Bd #
E4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
First Author: Benjamin L. Maughan
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
First Author: Evan Y. Yu
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2022 ASCO Annual Meeting
Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): A physician survey linked to patient chart reviews in the United States.
First Author: Stephen J. Freedland